OXB.L | Ticker Profile - Titan Protect

OXB.L

Oxford Biomedica plc

Healthcare · Biotechnology · LSE

$624.69

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$749M

Total market value of the company

Trailing P/E

N/A

Forward P/E

49.02

Based on estimated future earnings — lower means cheaper

Rev Growth

+22.5%

Year-over-year revenue change

Profit Margin

-17.9%

How much profit the company keeps from each dollar of revenue

ROE

-40.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$803.00

+29% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 7 analysts covering this stock

About Oxford Biomedica plc

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

https://www.oxb.com

Country: United Kingdom Employees: 977 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.989

Good returns relative to risk taken

Kelly Fraction

0.0305

Modest edge detected — smaller position warranted

Calmar Ratio

0.856

Acceptable balance between returns and drawdown risk

Annual Return

40.9%

Historical annualised return based on price data

Max Drawdown

-47.8%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.10

Moves slightly more than the broader market

52W High

$962.00

35% below the year high

52W Low

$305.50

104% above the year low

Avg Volume

262,999

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.27

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

162.16

Heavy leverage — higher financial risk if revenues decline

Current Ratio

2.20

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

1.92

Like current ratio but excludes inventory — stricter test

Gross Margin

39.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-7.9%

Profit from core operations before interest and tax

Free Cash Flow

$-13,250

Negative — the business is spending more than it generates

Revenue (TTM)

$169M

Total revenue over the last 12 months

Net Income

$-30,128,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$1,170.00

Target Median

$803.00

Target Low

$550.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go